This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Caffeine on Methacholine Challenge and Exhaled Nitric Oxide Levels.

This study has been completed.
Information provided by:
University of Saskatchewan Identifier:
First received: January 26, 2010
Last updated: October 5, 2010
Last verified: October 2010
To investigate whether or not the ingestion of caffeine with alter airway responsiveness to methacholine and/or change the level of exhaled nitric oxide.

Condition Intervention
Asthma Other: caffeine Other: No caffeine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: The Effects of Caffeine on Exhaled Nitric Oxide Levels and Methacholine PC20

Resource links provided by NLM:

Further study details as provided by University of Saskatchewan:

Primary Outcome Measures:
  • methacholine pc20 [ Time Frame: 1 hour post ingestion ]

Estimated Enrollment: 15
Study Start Date: January 2010
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: coffee with caffeine Other: caffeine
Starbuck's Grande Pike Roast coffee
Placebo Comparator: decaffeinated coffee
Starbuck's Grande Pike Roast Decaf
Other: No caffeine
Starbuck's Grande Pike Roast Decaffeinated Coffee


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnosis of asthma
  • FEV1 greater than 65%

Exclusion Criteria:

  • asthma is poorly controlled
  • presence of other airway disease (e.g. COPD)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01057875

Canada, Saskatchewan
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 0W8
Sponsors and Collaborators
University of Saskatchewan
Principal Investigator: Donald W Cockcroft, MD University of Saskatchewan
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Donald Cockcroft, MD, University of Saskatchewan Identifier: NCT01057875     History of Changes
Other Study ID Numbers: BIO REB 09-186
Study First Received: January 26, 2010
Last Updated: October 5, 2010

Additional relevant MeSH terms:
Nitric Oxide
Methacholine Chloride
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Protective Agents
Bronchoconstrictor Agents
Muscarinic Agonists
Cholinergic Agonists
Cholinergic Agents processed this record on August 18, 2017